Regeneron

Who are the 10 Most Innovative Biopharma Companies?
Who are the 10 Most Innovative Biopharma Companies?
BioSpace
innovation
Regeneron
Verily
Illumina
Biogen
Bayer
Bluebird Bio
Novartis
GSK
Genentech
Amgen
Flag link:
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations
Yahoo/Benzinga
JPMHC 2020
Bristol-Myers Squibb
Vertex Pharmaceuticals
Biomarin
Regeneron
Biogen
Alexion
Gilead Sciences
Amgen
Flag link:
Regeneron's bone disease drug delivers in phase 2, poised for FDA filing
Regeneron's bone disease drug delivers in phase 2, poised for FDA filing
Fierce Biotech
Regeneron
Rare Diseases
FDA
clinical trials
garetosmab
Flag link:
Regeneron to lay off field staffers as it restructures Sanofi partnership
Regeneron to lay off field staffers as it restructures Sanofi partnership
Fierce Pharma
Regeneron
Sanofi
layoffs
Flag link:
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent
Yahoo/Zacks.com
Sanofi
Regeneron
Kevzara
Praulent
Flag link:
Leo's Dupixent rival hits all endpoints in pivotal program
Leo's Dupixent rival hits all endpoints in pivotal program
Fierce Biotech
LEO Pharma
atopic dermatitis
tralokinumab
Sanofi
Regeneron
Dupixent
Flag link:
ASH2019 – Regeneron takes the bispecific baton and runs
ASH2019 – Regeneron takes the bispecific baton and runs
EP Vantage
ASH2019
Regeneron
Xencor
bispecific antibodies
REGN1979
lyphoma
Flag link:
Which asthma biologic do docs prefer? It's not that simple: analyst
Which asthma biologic do docs prefer? It's not that simple: analyst
Fierce Pharma
asthma
Roche
Novartis
Xolair
Sanofi
Regeneron
Dupixent
physicians
Flag link:
Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs
Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs
Fierce Pharma
Sanofi Genzyme
Regeneron
Dupixent
inflammation
Flag link:
Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat
Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat
Investor Place
Regeneron
earnings
Flag link:
Regeneron defends bid to challenge Merck in lung cancer
Regeneron defends bid to challenge Merck in lung cancer
Biopharma Dive
Regeneron
Libtayo
Merck
Keytruda
immuno-oncology
lung cancer
Flag link:
Regeneron profit beats expectations on Eylea, Dupixent strength
Regeneron profit beats expectations on Eylea, Dupixent strength
Yahoo/Reuters
Regeneron
earnings
Eylea
Dupixent
Flag link:
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
Yahoo/Zacks.com
Allergan
Regeneron
Mylan
Catalent
Jazz Pharmaceuticals
Flag link:
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Biopharma Dive
Regeneron
M&A
Eylea
Flag link:
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Biopharma Dive
Glenmark
Ichnos Sciences
India
Amgen
oncology
Regeneron
bispecific antibodies
Flag link:
Pfizer posts detailed phase 3 data on its Dupixent rival
Pfizer posts detailed phase 3 data on its Dupixent rival
Fierce Biotech
Pfizer
clinical trials
atopic dermatitis
abrocitinib
Dupixent
Sanofi
Regeneron
Flag link:
Eylea casts a shadow over Novartis' latest approval
Eylea casts a shadow over Novartis' latest approval
Biopharma Dive
Novartis
Beovu
wet age-related macular degeneration
Regeneron
Eylea
Flag link:
Novartis backs brolucizumab with new head-to-head Eylea trial
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
Flag link:
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Fierce Pharma
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
patents
Praluent
Repatha
Flag link:
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Fierce Pharma
Amgen
Regeneron
Sanofi
Praluent
Repatha
Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:

Pages